Mbappé Signs With On as Wells Fargo Turns on Netflix

On Holding shares rose 1.54% to 27.75 on Sept. 18, 2026 after signing Kylian Mbappé as a football partner, while Netflix fell 4.57% to 71.87 following a Wells Fargo downgrade to underweight and Xenon Pharmaceuticals dropped 30.18% after halting trial enrollment for azetukalner.

Three company-specific catalysts pulled in three directions on Friday, and none of them had much to do with the broad tape. On Holding (ONON) climbed on a football endorsement aimed squarely at the two companies that own the sport commercially. Netflix (NFLX) fell after a sell-side downgrade that questioned whether its slate is still producing the kind of shows that keep people watching. And Xenon Pharmaceuticals (XENE) lost roughly a third of its value after pulling back enrollment on the drug that defines its pipeline.

The indices, by contrast, barely moved with conviction. As of the last trade at 16:59 GMT on Sept. 18, 2026, the S&P 500 tracker (SPY) was at $759.40, down 0.42%; the Nasdaq 100 tracker (QQQ) was at $716.71, down 0.03%; and the Dow tracker (DIA) was at $515.23, down 0.60%. On a day like that, single-name moves of this size are the story.

On Holding buys a football face, not a football category

On Holding signed Kylian Mbappé as a partner to develop football products and represent the brand, a deal the company is positioning as a direct challenge to the grip Nike and Adidas hold over the sport. Shares were quoted at 27.75, up 1.54% from the prior close of 27.33, having traded between 27.02 and 28.38 on the session.

The modest size of that move is itself informative. A single endorsement, however large the name, does not hand a brand a boot business. Football is the most institutionally locked category in athletic footwear: club kit deals, federation contracts, national-team supply and academy pipelines are signed years out, and the incumbents have spent decades building them. Signing the most recognisable attacking player in the game buys visibility and product credibility. It does not buy shelf space at a club's equipment room.

What the market appears to be pricing is optionality rather than revenue. On built its identity in running, where a technical story and a premium price point could be argued on their merits. Football asks a different question — whether a performance brand can be adopted by players and then by the teenagers who copy them. Mbappé is the fastest available route to the second half of that sequence. The first half still requires boots that professionals choose, and those take time to iterate.

Investors watching this one should track product launches and, more tellingly, the number of visible on-pitch users at top-flight level over the next two seasons. Endorsement spend shows up in operating costs immediately; category share shows up much later.

Wells Fargo says Netflix needs a hit, not a strategy

Netflix was the day's most consequential decline among the three. Shares were quoted at 71.87, down 4.57% from the prior close of 75.31 — a drop of 3.44 points on the session, with the stock ranging between 70.11 and 73.45. The trigger was a Wells Fargo downgrade to underweight, with analyst Steven Cahall pointing to user engagement as the core worry. Cahall wrote that Netflix "has lacked big original series and it's showing," and that "breakout hits" are necessary for the stock to work again, according to Bloomberg Markets.

That framing is a sharper critique than a typical valuation call. A downgrade on multiple says the price is wrong. A downgrade on engagement says the product is. Engagement is the variable that sits upstream of nearly everything in the streaming model: hours watched support retention, retention supports the ability to raise prices without churn, and total hours determine how much advertising inventory there is to sell. If the slate is not generating shows people talk about, the pressure eventually reaches subscriber economics and the ad tier at the same time.

It is also a call that can be falsified quickly, which cuts both ways. A single genuine cultural hit would undercut the thesis within a quarter. The absence of one for several more quarters would validate it decisively. For holders, the practical watch items are management's commentary on viewing hours, the cadence of returning franchise seasons, and whether price increases start to show up alongside softer net additions.

Xenon's decline shows what single-asset biotech risk looks like

Xenon Pharmaceuticals was the most violent mover of the three. The stock was quoted at 40.04, down 30.18% from a prior close of 57.35 — a fall of 17.31 points — after trading as low as 39.65 and as high as 44.86. The company voluntarily halted trial enrollment for azetukalner, a candidate targeting depression and bipolar disorder, after studies showed adverse events.

A one-third haircut on an enrollment pause rather than a formal trial failure tells you how concentrated the valuation was. When a clinical-stage company's worth rests largely on one molecule across one or two large indications, safety signals are repriced as existential rather than incremental. The word "voluntarily" matters procedurally — it signals the sponsor acted before a regulator or data monitoring committee compelled it — but it does not soften the commercial arithmetic, because psychiatric indications carry unusually demanding safety bars. These are chronic conditions treated in large outpatient populations, often with existing generic options, so tolerability is not a secondary consideration.

What comes next is a timeline question. Investors will want to know the nature and severity of the adverse events, whether enrollment resumes with protocol changes, and how far any restart pushes readouts and filings. Each month of delay is a month of cash burn against an unchanged pipeline.

One session, three different clocks

The three names share a structure worth noting: in each case, the market repriced the odds on a future event rather than a reported number. On's payoff arrives over seasons, Netflix's over a slate cycle, Xenon's over a regulatory and clinical calendar. That is why the sizes differ so much. An endorsement moved a stock 1.54%; an analyst's view on content moved one 4.57%; a paused trial at a single-asset biotech moved one 30.18%. The magnitude of each reaction is a fair proxy for how much of the company's value depends on the thing that changed.

Key facts

• ONON: 27.75, +1.54% (last trade 16:59 GMT, Sept. 18, 2026); prev close 27.33
• NFLX: 71.87, -4.57% (last trade 16:59 GMT, Sept. 18, 2026); prev close 75.31
• XENE: 40.04, -30.18% (last trade 16:59 GMT, Sept. 18, 2026); prev close 57.35
• Downgrade: Wells Fargo's Steven Cahall cut Netflix to underweight on user engagement concerns

Frequently asked questions

Why did On Holding shares rise on Sept. 18, 2026?

On Holding signed footballer Kylian Mbappé as a partner to help develop football products and represent the brand. The market read it as a push into a category dominated by Nike and Adidas. Shares were quoted at 27.75, up 1.54% from the prior close of 27.33, with an intraday range of 27.02 to 28.38.

What did Wells Fargo say about Netflix?

Wells Fargo downgraded Netflix to underweight, citing concerns about user engagement. Analyst Steven Cahall wrote that Netflix "has lacked big original series and it's showing" and that "breakout hits" are necessary for the stock to work again. Netflix shares fell 4.57% to 71.87 following the call.

Why did Xenon Pharmaceuticals fall so sharply?

Xenon voluntarily halted trial enrollment for azetukalner, a candidate treating depression and bipolar disorder, after studies showed adverse events. The stock dropped 30.18% to 40.04 from a prior close of 57.35. The scale of the decline reflects how much of the company's valuation rested on that single asset.

Does the Mbappé deal mean On can compete with Nike and Adidas in football?

Not immediately. Football is governed by long-dated club, federation and kit supply contracts that incumbents have held for decades. An endorsement delivers visibility and product credibility, but category share depends on boots professionals actually choose and on distribution. The 1.54% share move suggests investors priced optionality rather than near-term revenue.

Why is engagement a more serious concern for Netflix than valuation?

Engagement sits upstream of the whole model. Hours watched drive retention, retention determines whether price increases stick without churn, and total viewing sets how much advertising inventory exists to sell. A valuation downgrade says the price is wrong; an engagement downgrade questions whether the product itself is producing the results that support pricing power.

How did the broad market perform that session?

Benchmark trackers were modestly lower as of the last trade at 16:59 GMT on Sept. 18, 2026. The S&P 500 tracker (SPY) was at $759.40, down 0.42%. The Nasdaq 100 tracker (QQQ) was effectively flat at $716.71, down 0.03%. The Dow tracker (DIA) stood at $515.23, down 0.60%.

Sources

• On Holdings New Partner; Netflix Analyst Downgrade | Stock Movers — Bloomberg Markets